Ton Adang
Corporate Officer/Principal presso LAVA THERAPEUTICS N.V.
Patrimonio netto: 1 808 $ in data 31/05/2024
Posizioni attive di Ton Adang
Società | Posizione | Inizio | Fine |
---|---|---|---|
LAVA THERAPEUTICS N.V. | Corporate Officer/Principal | 01/07/2017 | - |
Storia della carriera di Ton Adang
Precedenti posizioni note di Ton Adang
Società | Posizione | Inizio | Fine |
---|---|---|---|
EnCare Biotech BV
EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Direttore operativo | 01/08/2014 | 01/12/2017 |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Direttore operativo | 01/10/2012 | 01/10/2017 |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Corporate Officer/Principal | 01/08/2014 | 01/09/2016 |
Simibio BV
Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Direttore operativo | 01/07/2011 | 01/06/2014 |
MERCK KGAA | Corporate Officer/Principal | 01/11/2009 | 01/03/2010 |
Formazione di Ton Adang
Wageningen University | Graduate Degree |
University of Leiden | Doctorate Degree |
Statistiche
Distribuzione geografica
Paesi Bassi | 8 |
Germania | 2 |
Posizioni
Chief Operating Officer | 3 |
Corporate Officer/Principal | 3 |
Graduate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
LAVA THERAPEUTICS N.V. | Health Technology |
MERCK KGAA | Health Technology |
Aziende private | 4 |
---|---|
Simibio BV
Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Health Technology |
EnCare Biotech BV
EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Ton Adang
- Esperienza